Lipimet SR (atorvastatin/metformin) / Daewoong Pharma - LARVOL DELTA

Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3) (clinicaltrials.gov) - P3 | N=185 | Completed | Sponsor: Daewoong Pharmaceutical Co. LTD. | Unknown status ➔ Completed

Combination therapy • Trial completion • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus • APOA1

Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets. (PubMed, Drug Des Devel Ther) - "Study 2, a randomized, open-labeled, single-dose, two-treatment, two-period, two-sequence crossover study, involved 27 healthy subjects to investigate the impact of food intake on the pharmacokinetics of a combined atorvastatin/metformin XR 20/500 mg (CJ-30056 20/500 mg) tablet. Food appeared to change the absorption of atorvastatin and metformin from an FDC formulation. These alterations were in accordance with those described with the single reference drugs when ingested with food."

Clinical • Journal • PK/PD data